Physician profile
Sukrut Dwivedi
NPI 1003082660
$75,037.96
in general payments reported to CMS, 2019-2025
23 companies · $7,396 in 2025
The $7,396 reported for 2025 was more than what 91% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $7,032 · 2021: $17K · 2022: $16K · 2023: $7,172 · 2024: $4,462 · 2025: $7,396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $2,174 · Consulting Fee: $1,625 · Travel and Lodging: $906 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,250.00 |
| Food and Beverage | $2,173.65 |
| Consulting Fee | $1,625.00 |
| Travel and Lodging | $906.15 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $24,113.32 | 2020-2024 | Nuzyra |
| Abbvie INC. | $24,013.47 | 2019-2025 | Dalvance, Avycaz, Teflaro |
| Allergan, INC. | $16,081.49 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $6,424.42 | 2019-2025 | Pifeltro, Dificid, Zerbaxa |
| Viiv Healthcare Company | $2,533.60 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $568.94 | 2019-2025 | Biktarvy, Veklury |
| Insmed, INC. | $401.18 | 2019-2025 | Arikayce |
| Aimmune Therapeutics, INC. | $165.14 | 2023-2025 | Vowst |
| Melinta Therapeutics, LLC | $124.67 | 2019-2023 | Vabomere, Orbactiv, Kimyrsa |
| Silk Road Medical, INC. | $122.04 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Smith+Nephew, INC. | $111.29 | 2019 | |
| Astellas Pharma US INC | $75.03 | 2019-2024 | Cresemba |
| Theratechnologies INC. | $70.13 | 2023-2025 | Trogarzo, Egrifta |
| Janssen Biotech, INC. | $60.34 | 2021-2023 | Symtuza |
| Shionogi INC | $54.02 | 2023-2024 | Fetroja |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $19.09 | 2019 | |
| Ferring Pharmaceuticals INC. | $16.92 | 2023 | Rebyota |
| Tetraphase Pharmaceuticals, INC. | $14.86 | 2019 | |
| Dynavax Technologies Corporation | $14.76 | 2023 | Heplisav-B |
| Vyera Pharmaceuticals, LLC | $14.34 | 2019 | |
| Nabriva Therapeutics, Plc | $14.01 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.90 | 2022 | |
| Romark Laboratories, Lc | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sukrut Dwivedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.